Her var endpoint (12- månders persisterende infektion for HPV- 18) statistisk signifikant med en vaccineeffekt på 89, 9% (97, 9% CI; 11, 3- 99, 9).
6 TVC-1 analysis except that it excluded women with abnormal cytology at study entry, the 12 month persistent infection endpoint for HPV-18 reached statistical significance with vaccine efficacy of 89.9% (97.9% CI: